You can access the annual and quarterly cash flow statements of Drugs Made In America Acquisition Corp to evaluate its financial soundness and stability.
Quarterly
Quarterly+Annual
Quarterly
Annual
YOY
Hide blank rows
FY2026Q1
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
Operating cash flows (indirect method)
Cash flow from continuing operating activities
63.68%-91.25K
---125.18K
---56.11K
---106.66K
---251.24K
Net income from continuing operations
57.07%1.97M
--212.96K
--2.18M
--2.29M
--1.25M
Other non-cash items
-68.28%30.00K
--2.02M
--31.00K
---10.90K
--94.57K
Change in working capital
248.06%22.05K
---59.01K
--176.59K
--36.16K
---14.89K
-Change in prepaid expenses
108.64%6.05K
--21.43K
--21.43K
--21.19K
---70.10K
-Change in payables and accrued expense
-71.02%16.00K
---80.44K
--155.17K
--14.97K
--55.20K
Cash from non-recurring investing activities
Cash from operating activities
63.68%-91.25K
---125.18K
---56.11K
---106.66K
---251.24K
Investing cash flow
Net cash flow from investment products
----
--0.00
--0.00
--0.00
---231.15M
Net cash flow from other investing activities
----
----
--0.00
----
----
Cash from non-current investing activities
Net cash flow from investing activities
----
--0.00
--0.00
--0.00
---231.15M
Financing cash flow
Cash flow from continuous financing activities
-99.96%100.00K
--130.60K
--56.00K
--106.55K
--231.40M
Net cash flow from debt Issuance/repayment
111.11%100.00K
--0.00
--0.00
--0.00
---900.00K
Net cash flow from other financing activities
-100.00%0.00
--130.60K
--56.00K
--106.55K
--232.30M
Net cash from non-recurrent financing activities
Net cash from financing activities
-99.96%100.00K
--130.60K
--56.00K
--106.55K
--231.40M
Net cash flow
Beginning cash balance
354.26%6.14K
--717.00
--822.00
--923.00
--1.35K
Current period cash flow changes
2144.39%8.75K
--5.42K
---105.00
---101.00
---428.00
Ending cash balance
1512.89%14.89K
--6.14K
--717.00
--822.00
--923.00
Free cash flow
----
---125.18K
---56.11K
---106.66K
---251.24K
Currency unit
--USD
--USD
--USD
--USD
--USD
Audit opinions
----
----
----
----
----
FAQs
What is operating cash flow?
Operating cash flow is the cash generated or used by a company's core business operations. It adjusts net income for non-cash items and working capital changes, such as depreciation, receivables, inventory, and payables. Strong operating cash flow can indicate that the business is converting sales and earnings into real cash.
How Much Operating Cash Flow Did Drugs Made In America Acquisition Corp Generate?
Drugs Made In America Acquisition Corp generated -539.19K in operating cash flow in fiscal 2025, reflecting cash generated from its core business operations.
How Did Drugs Made In America Acquisition Corp's Operating Cash Flow Change Year Over Year?
Drugs Made In America Acquisition Corp's operating cash flow increased by -213.00% year over year.
What is investing cash flow?
Investing cash flow shows cash used for or generated from investment-related activities, such as capital expenditures, purchases or sales of investments, acquisitions, and asset disposals. Negative investing cash flow is not always bad, because it can reflect spending on future growth, but investors should check whether those investments support long-term returns.
What is financing cash flow?
Financing cash flow shows how a company raises capital or returns capital to investors and creditors. It can include debt issuance, debt repayment, share issuance, share repurchases, dividend payments, and lease financing. Positive financing cash flow may show new capital raised, while negative financing cash flow may reflect debt repayment, dividends, or buybacks.
How Has Drugs Made In America Acquisition Corp's Financing Cash Flow Changed?
Drugs Made In America Acquisition Corp used 231.69M in financing activities in the latest quarter.
What is free cash flow and why does it matter for DMAA?
Free cash flow is the cash a company has left after funding the capital spending needed to maintain or grow the business. It is often used to assess financial flexibility, debt repayment capacity, dividend sustainability, buyback potential, and valuation quality. Investors should compare free cash flow with net income, revenue growth, and capital expenditures.